RET and neoplasm: We predicted RET inhibitors pralsetinib and selpercatinib among the top ten most effective in both pituitary and lung ACTH-secreting tumors, with the RET gene upregulated in 15/16 pituitary and 6/6 lung ACTH-secreting tumor cases investigated.